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Our  aim  with  the  present  study  was  to  evaluate  rank-order  and  mean-level  cognitive
functioning  stability among  first-episode  psychosis  (FEP)  patients,  measured  using  the
Cambridge  Neuropsychological  Test  Automated  Battery  (CANTAB),  over  a  six  month
period. We also aimed to examine longitudinal measurement invariance and identify factors
—such as age, gender, educational level, treatment and psychopathological change scores—
potentially  linked to  cognitive  change among patients.  In  addition,  correlations  between
objectively  measured  and  subjectively  evaluated  cognitive  functioning  were  estimated.
Neuropsychological  assessments  were  administered  to  85  patients  after  the  initial
stabilisation  of  their  psychosis;  82  of  the  patients  were  retested.  Subjectively  perceived
cognitive functioning was measured using a subscale derived from the Estonian version of
the  Subjective  Well-Being  Under  Neuroleptic  Scale  (SWN-K-E).  On  average,  executive
functioning  and  processing  speed  improved  significantly,  while  memory  test  scores
decreased  significantly,  over  time.  Very  high  rank-order  stability  (r =  0.80  to  0.94,
p < 0.001)  was  observed  with  all  measured  ability  scores.  Confirmatory  factor  analysis
revealed  the  loadings  of  a  single  (broad  ability)  factor  model  were  equal  across  both
measurement  occasions,  but  the  lack  of  intercept  invariance  suggested  that  mean-level
comparisons  are  more  appropriately  carried  out  at  a  subtest  level.  On  average
psychopathology scores and antipsychotics doses declined over time, with the latter also
significantly  correlating  with  better  executive  functioning.  Gender  was  a  significant
moderator of some domains of cognitive performance, and decline tended to be somewhat
more pronounced for women. The results also indicated the lack of any relationship between
objective and subjective measurements of cognitive functioning. 




Among  other  symptoms,  psychotic  illnesses  are  accompanied  by  neuropsychological
impairments  (Green  et  al.,  2004;  Kurtz,  2005).  Although  individual  patient’s
neuropsychological profiles may be heterogeneous  (Joyce et al., 2005), they are typically
characterised  by  attention,  set  shifting,  processing  speed,  memory,  learning,  working
memory, and executive function deficits  (Heinrichs and Zakzanis, 1998; Mesholam-Gately
et al., 2009; Saykin et al., 1991), something that can be broadly summarised as generalised
cognitive  impairment  (Dickinson  et  al.,  2004;  Mohamed  et  al.,  1999).  On  average,
schizophrenia patients tend to score 1.0 to 2.5 standard deviations lower in general cognitive
ability compared to control subjects (CoS), however there is also some variability in the
extent of impairment between domains (Bilder et al., 1992; Heinrichs and Zakzanis, 1998;
Keefe, 2014; Mohamed et al., 1999). While some patients do fall within the normal range of
±1 standard deviations of the mean of a generally healthy population (Kremen et al., 2000;
Palmer et  al.,  1997). Hoff et al.  (2005) concluded that although most FEP patients have
undergone considerable cognitive decline by the time of their first hospitalisation, the exact
course of cognitive impairment remains unknown. In addition,  psychotic symptoms may
even  share  some  genetic  aetiology  with  cognitive  functioning  (Kendler  et  al.,  2015;
McIntosh et al., 2013). 
The available evidence is also contradictory as to whether cognitive functioning continues to
decline during later stages of schizophrenia (Aas et al., 2014; Rund et al., 2007). It has been
argued that the majority of such cognitive declines occurs just before or within a few years
after the onset of psychosis  (Bora and Murray, 2014). To date, longitudinal studies have
investigated patients’ cognitive functioning over the years following disease onset, but less
is  known about  what  specifically  happens  to  their  cognitive  abilities  during  the  months
immediately following FEP diagnosis.  Investigating the cognitive performance of patients
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during the early stages of chronic psychotic disorder may help to identify cognitive deficits
related to schizophrenia, compared to cognitive dysfunction resulting from the long-term
course of the schizophrenic illness or the treatment of either. 
During the present study we investigated cognitive changes among FEP patients following
their  FEP.  First,  mean-level  changes  were  calculated  to  ascertain  the  extent  to  which
patients’ cognitive abilities had changed during the six months following FEP. Second, the
extent to which patients retained their cognitive test score ranking (rank-order stability) was
examined. The lower the stability, the more likely there are potentially identifiable factors
that  result  in deviation from the normative change pattern of a condition (Deary, 2014).
Third,  the  structure  of  changes  were  examined,  indicating  the  extent  to  which  changes
happened  in  lockstep,  and  therefore  were  likely  to  pertain  to  cognitive  functioning  in
general,  as  opposed  to  specific  cognitive  domains.  Fourth,  individual  differences  in
cognitive  changes  were  compared  to  possible  causal  factors,  including  demographic
characteristics,  antipsychotic  medication  dosages,  and the  extent  of  psychopathology. In
addition to cognitive functioning quantified using objective performance tests, subjective
cognitive  dysfunction  may  be  an  important  early  indicator  of  schizophrenia,  as  it  can
precede prodromal symptoms (Hambrecht et al., 2002; Nuechterlein and Dawson, 1984) is
prevalent among patients with FEP (Moritz et al., 2000) and in the late stages of the disorder
(Homayoun et al., 2011; Stip et al., 2003). During the present study, changes in subjective
cognitive dysfunction were also recorded over the same timeframe. As it is currently unclear
to what extent subjective and objective cognitive dysfunction measurements are in-line each
other—some studies  report  positive  correlations  (Prouteau,  2004;  Stip  et  al.,  2003) and
others no significant correlations (Homayoun et al., 2011; Zanello and Huguelet, 2001)—we
correlated levels  of  change between  measurements of  objective and subjective cognitive
dysfunction.
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2. Materials and Methods
Study participants 
The FEP patients were part  of  an on-going longitudinal research project of first-episode
psychosis conducted by the Psychiatry Clinic of Tartu University Hospital, Estonia. A total
of 85 patients (mean age 26.99 years old, s.d. = 6.96, range 18–43; 54.12% male; 92.94%
right-handed) met the inclusion criteria: aged between 18 and 45; had experienced FEP; the
duration of untreated psychosis was less than three years; they had received no antipsychotic
treatment  before  their  first  contact  with  medical  services  for  psychosis.  At  the  time  of
recruitment,  patients  were  in  a  stabilisation  phase  of  the  disease,  with  the  initial  florid
psychotic symptoms had been controlled by medication.  Diagnoses were based on clinical
interviews  that followed ICD-10 (WHO,1992)  criteria,  a review of their medical history,
information  from family  members,  and  were  agreed  upon  by two  clinical  psychiatrists.
Among  the  patients,  the  diagnoses  were:  acute  polymorphic  psychotic  disorder  without
symptoms of  schizophrenia  (F23.0,  n =  16);  acute  polymorphic  psychotic  disorder  with
symptoms of  schizophrenia (F23.1,  n = 16);  acute  schizophrenia-like  psychotic  disorder
(F23.2,  n = 21);  other acute predominantly delusional psychotic disorder (F23.3,  n = 4);
other acute and transient psychotic disorders (F23.8, n = 5); paranoid schizophrenia (F20.09,
n = 19); catatonic schizophrenia (F20.29, n = 1); undifferentiated schizophrenia (F20.39, n =
2); other nonorganic psychotic disorders (F28, n = 2). F20.39 and F28 category patients had
experienced psychotic symptoms for longer than one month. The patients had received an
average of 21.42 (s.d. = 8.92) days of treatment prior to baseline neuropsychological testing.
Follow-up  data  were  collected  approximately  six  months  later  (mean  duration  between
baseline and follow-up testing was 6.35 (s.d. = 0.91) months. Follow-up data were available
for a total of 82 patients (96.47%); two patients had dropped-out of the mental health care
system, and one declined. Patients were being treated with various atypical antipsychotic
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medications as appropriate to their specific condition. At baseline, all patients were receiving
only atypical antipsychotics;  at  follow-up, four patients (4.88%) were additionally  being
treated with neuroleptics. Neuropsychological assessments were performed when patients
were clinically stable and willing to undergo the procedure. All FEP patients were fluent in
Estonian, and had on average undergone 13.04 (s.d. = 2.51) years of fulltime education. 
With regard to substance abuse, ten patients (11.8 %; seven males) reported having tried
cannabis;  nine  patients  (10.6%;  all  male)  reported  having  habitually used  cannabis  and
amphetamine type stimulants at some point during their lifetime. None of the patients  met
substance dependence criteria.  
The  study  was  approved  by  the  Ethics  Review Committee  on  Human  Research  of  the
University of Tartu (Estonia) and carried out in accordance with The Code of Ethics of the
World Medical Association. A complete description of the purpose and procedures of the
study was read to the participants, and written informed consent provided by all. Participants
were  recruited  between  March 2009  and  June  2015.  The  same sample  has  been  partly




A number  of  studies  have  used  the  comprehensive  Cambridge  Neuropsychological  Test
Automated  Battery  (CANTAB)  (Robbins  and  Sahakian,  1994) to  produce
neuropsychological profiles that characterise FEP patients (Barnett et al., 2005; Haring et al.,
2015b; Hutton et al., 1998; Leeson et al., 2009a). The CANTAB tests are administered using
a computer with a touch-sensitive screen; application of the test and feedback are given in a
standardised manner, which precludes examiner variation (Fray et al., 1996). The CANTAB
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has different forms for a certain subtest and adult population validity estimates, and for some
subtests test–retest reliability indices are provided (Lowe and Rabbitt, 1998). However, the
equivalence of these alternate forms, as well as their psychometric properties among an FEP
group, have not been empirically established.
Eight  CANTAB tests,  shown to be  sensitive  to  evaluating  the  cognitive  dysfunction  of
patients with psychotic disorders, were administered  in a fixed order to each patient  in a
one-to-one setting.   The tests (see below) were run using  CANTABeclipse Version
3.0.0.  All  task  stimuli  were  visual  in  nature,  consisting  of  geometric  designs  or  simple
shapes,  and required  a  non-verbal  response.  Instructions  were given in  Estonian from a
literal  translation  of  the  CANTAB  test  manual  that  was  produced  by  three  clinical
psychologists fluent in both English and Estonian.  The battery of tests took approximately
one hour to administer. During test sessions, participants were offered  to take a short
break whenever they felt the need. 
Visual memory tests 
Pattern  recognition  memory  (PRM) tests  rely  on  cued  memory  functions,  and the  total
number of correct responses was used as the outcome in the present analyses. 
Spatial recognition memory (SRM) tasks measure a subject’s spatial memory via a forced-
choice paradigm.  The total number of correct responses was used as the outcome in the
analyses.
Paired-associates learning  (PAL) tests assess visual memory and new learning.  The first
trial memory score was used as the outcome of this test.
Executive function, planning, and working memory tests
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Intra/extradimensional shift (IED) tests assess visual discrimination, selective attentional set
formation and maintenance, shifting, and flexibility of attention; the number of errors made
in the extra-dimensional stage of the task was recorded as the outcome of the present study,
and all participants reached this level of the task. 
Stockings of Cambridge (SOC) is a spatial planning test, and the number of problems solved
with minimal moves was recorded as the outcome. 
Spatial span  (SSP) assesses subjects’ visuospatial short-term memory.  The number of
successes (in terms of being within a certain span length) was recorded. 
Spatial working memory (SWM) tests evaluate subjects’ ability to retain spatial information
and manipulate these remembered items in their working memory. The number of errors was
recorded, as well as a strategy score that consisted of the number of times an ineffective
strategy was used. 
Speed of processing
Rapid visual  information processing  (RVP) tests  involve a  sustained vigilance task.  The
probability of a correct hit (sensitivity for detecting sequences) was recorded as the outcome.
During the follow-up assessments, alternate test versions of PRM, SRM, PAL, and IED were
used.  For  more  detailed  descriptions  of  these  tests,  see  the  CANTAB  website
(http://www.cambridgecognition.com). 
Clinical assessments
Range and severity  of  psychopathology was assessed using the Brief  Psychiatric  Rating
Scale (BPRS)  (Overall and Gorham, 1962).  The BPRS consists of 18 symptoms and each
item is measured on a seven-point Likert scale from “not present” to “extremely severe”. A
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total  score,  as  well  as  positive  and  negative  BPRS  symptom  scores  (derived  from  the
subscales identified by Ventura et al. (2000)), were used as the outcome. 
Medication data
Types and dosage of antipsychotic medications were recorded and subsequently converted
into mean theoretical chlorpromazine (CPZ) equivalents (Gardner et al., 2010).
Subjective cognitive functioning
Patients’  subjectively  perceived  cognitive  functioning  was  evaluated  using  a  ‘Mental
functioning’ subscale,  obtained from the Subjective Well-being under  Neuroleptics-Short
Form (SWN) (Naber et al., 2001), Estonian version (Haring et al., 2013). The SWN consists
of  20  items  rated  on  a  6-point  Likert  type  self-rating  scale  that  refers  to  subjective
experiences during the past seven days. The ‘Mental functioning’ subscale comprises four
items: “I find it easy to think”; “I am imaginative and full of ideas”; “My thinking is difficult
and slow”; “My thoughts are flighty and undirected,  it  is difficult  to think clearly”. The
values of the last two items were reversed during scoring and this global score was a more
useful indicator of subjective mental functioning.  
Statistical analysis
Ability test scores on both testing occasions were standardised in relation to the means and
standard  deviations  of  the  first  testing  occasion,  so  that  the  mean  scores  at  follow-up
represented changes in standard deviation units. However, to control for age, gender, and
educational level, mean-level differences were estimated using random coefficients models
(RCM), whereby the testing occasion was a categorical predictor of the respective test scores
(with effect size representing the mean difference in standard deviation units of the first
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testing); age, gender, and educational level were covariates and the intercepts were allowed
to vary across individuals. Effect sizes were interpreted as small, moderate, and large, with
corresponding  Cohen’s  d ranging  from  0.20–0.49,  0.50–0.79,  and  ≥0.80,  respectively
(Cohen, 1977). Mean-level changes in BPRS and CPZ dose equivalents were also estimated
using a similar RCM; as CPZ dose equivalents already represent standardised values, raw
data were used.  Next, we examined rank-order stability across the two testing occasions
using Pearson’s correlation. Then, general linear models (GLM) were performed to quantify
individual-level changes in cognitive ability test scores over time, whereby follow-up scores
controlled for age, gender, and educational level were predicted from the baseline scores;
deviations from individual’s predicted scores (regression residuals) at follow-up were taken
as their individual change score (CSs). Principal component analysis (PCA) was then used to
investigate the structure of the CSs. We have previously demonstrated (Haring et al., 2015b)
that different ability test scores were more strongly intercorrelated among patients than CoS;
here we focused on the changes in scores over time. Following the PCA, the replicability of
the cognitive traits structure between the two testing occasions (Widaman et al., 2010) was
evaluated  using  multi-group (groups  represented  occasions)  confirmatory  factor  analysis
(CFA).  Initial  model  fit  (configural  invariance  with  no  parameter  equality  constraints
imposed) was assessed using the comparative fit index (CFI) (Bentler, 1990), and the root
mean square error of approximation (RMSEA) (Hu and Bentler, 1999). Goodness of fit is
indicated by values ≥0.95 for CFI, and ≤0.06 for RMSEA  (Hu and Bentler, 1999). After
configural  invariance  was  evaluated,  weak  measurement  invariance  (equality  of  factor
loadings) between the six month time interval was tested using chi-square difference (Δχ2)
and CFI difference (ΔCFI) (Horn and McArdle, 1992; Vandenberg and Lance, 2000), where
Δχ2  of p  < 0.05 and  ΔCFI of > 0.01  indicated a statistically significant difference in fit.
Models were fitted using the maximum-likelihood estimator using the ‘lavaan’ package of R
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(Rosseel, 2012). Next, to evaluate whether a significant changes in cognitive characteristics
were correlated with age, gender, educational level, clinical symptom severity, or treatment-
related  variability,  a  psychopathology  change  scores  (BPRS  CSs)  and  antipsychotics
equivalent  dose change scores  (AP DCs) were  calculated,  and cognitive  CSs separately
regressed with BPRS CSs, AP DCs, and demographic variables, using RCM.
Finally,  separate  Pearson’s  correlations  between  cognitive  test  scores  and  subjectively
perceived mental functioning at baseline and six month follow-up were performed. 
All analyses were conducted using R Statistical software (R Core Team, 2015). 
3. Results
3.1. Patients characteristics
Females were older (27.49 years old, s.d. = 7.05) than males (26.57 years old, s.d. = 6.94)
and had undergone more formal education (mean for females: 13.51 years, s.d. = 2.16; mean
for  males:  12.64  years,  s.d.  =  2.72),  although  these  differences  were  not  statistically
significant  (t =  -0.61,  p =  0.55;  t =  -1.61,  p =  0.11,  respectively).  Mean  general
psychopathology score,  measured using BPRS, was 24.18 (s.d.  = 12.80) at  baseline and
19.31 (s.d. = 11.37) at follow-up (t = -4.24,  p < 0.0001). Total BPRS CSs was statistically
significant (t = 7.52, p < 0.00001); gender was not a significant predictor (t = -1.45, p = 0.15)
of CSs. BPRS negative and positive symptoms subscale mean scores at baseline were 3.98
(s.d. = 2.91) and 5.20 (s.d. = 3.65), and during follow-up 4.27 (s.d. = 3.10) and 3.56 (s.d.
3.50), respectively. BPRS negative and positive symptoms change scores (CSs) between the
two occasions were statistically significant  (t = 7.15,  p < 0.00001;  t = 6.51,  p < 0.00001,
respectively). Gender differences were not significant for either negative (t = 0.93; p = 0.36)
or positive (t = -1.04; p = 0.30) psychopathology CSs. The mean theoretical chlorpromazine
(CPZ) dose equivalents of antipsychotic medications were 387.38 mg/day (s.d. = 165.44) at
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baseline and 319.97 mg/day (s.d. = 183.31) at follow-up. There was significant change in AP
DCs between the two testing occasions (t = 3.41,  p = 0.001); gender was not a significant
predictor (t = 0.45, p = 0.66). 
3.2. Mean-level change  
When patients’ mean-level changes over the six month period were examined (Table 1),
small  increases  in  set-shifting  (IED),  speed  of  processing  (RVP),  executive  functioning
(SOC),  as  well  as in strategy usage and the ability  to  manipulate  spatial  information in
working  memory  (SWM) appeared.  In  addition,  there  were  large  effect  sizes  for  lower
performance  in  episodic  memory  (PAL)  and  spatial  recognition  memory  (SRM)  tasks.
Spatial working memory (SSP) and pattern recognition memory (PRM) tests showed mean-
level stability over time. 
3.3. Stability of cognitive functioning  
We examined the rank-order stability of cognitive functioning over the test–retest interval of
six months. The rank-order stability coefficients (Table 1) of the cognitive tests ranged from
r = 0.80 to 0.94, all significant at p < 0.001. Therefore, patients’ relative standings regarding
test performance were very stable, suggesting that mean-level changes tended to characterise
most  of  patients  in  a  similar  way.  These  estimates  also  represent  the  lower-boundary
estimates of the reliability of tests in psychotic patients.
3.4. Structure of cognitive function and measurement invariance
The one-factor (broad ability factor) solution accounted for 19% of total variance among the
eight  CANTAB subtest  scores in  the baseline assessment of the FEP patient group, and
primary loading values ranged between 0.13 and 0.82 (Figure 1). 
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The dimension identified by the PCA was assumed to reflect an underlying broad cognitive
ability trait. The plausibility of the model was estimated using CFA, which confirmed that
the empirical model in which measures of CANTAB subtests were loaded on one broad
ability domain demonstrated an excellent fit for the data (χ2 = 25.451; df = 27; CFI = 1.000;
RMSEA = 0.000; 90% confidence interval for RMSEA = 0.000–0.079). 
We  then  conducted  a  series  of  two  time-point  factor  analyses  across  three  levels  of
invariance testing,  by first  evaluating the  absolute  model  fit  at  each  level  of  invariance
testing, and then calculating the relative fit of each nested model. Using the criteria of an
RMSEA of  ≤0.06  and  CFI  of  ≥0.90  to  evaluate  absolute  model  fit,  we  found  that  the
hypothesised one-factor model demonstrated an excellent fit (CFI = 0.950; RMSEA = 0.058;
90%  confidence  interval  for  RMSEA =  0.000–0.095;  Table  2),  suggesting  it  could  be
considered  a  feasible  representation  of  the  data  at  both  time-points  and  justifying  the
evaluation of more restrictive invariance models.  At the level of  weak invariance testing,
model fit remained acceptable (Table 2), indicating that estimated factor loadings were not
significantly different between the two time-points. Indices of both relative and absolute
model  fit  did not  support the existence of  scalar invariance,  i.e.  intercept  values  varied
significantly between the two assessments. As scalar measurement invariance was not met,
testing for stricter forms of invariance were not justified.
3.5. The relationship of cognitive stability with other variables
As described above, for SRM, PAL, IED, SOC, SWM errors, and strategy usage the models
reached statistical significance. In order to test whether these changes were moderated by
demographic variables (age, gender, educational level), BPRS CSs and AP DC CSs we used
RCM analyses. Details of these results are provided in Table 3. Gender was a significant
predictor of IED, SOC, SSP, and SWM test performances. Specifically, Figure 2. shows that
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gender differences at baseline levels of performance (a) and longitudinal rates of change (b)
were significant for the IED, SOC, SSP, and SWM tests, with males outperforming females.
Therefore, cognitive decline tended to be somewhat more pronounced among the female
patients. In addition, longer time in education was predictor for smaller change in IED, and
bigger change in the RVP test performances. Younger age was associated with extensive
changes in SRM, PAL, and SSP tests’ performances and older age predicted bigger change
in strategy score in SWM test. 
BPRS  CSs  was  not  found  to  be  a  significant  predictor  of  any  cognitive  test  CSs.  We
conducted additional RCM analyses to separately evaluate the BPRS negative and positive
symptoms CSs effects (in addition to gender, age, education and AP DCs) on the cognitive
tests  CSs.  We did  not  detect  statistically  significant  impact  of  negative  symptoms CSs,
measured  by  BPRS  negative  symptoms  subscale,  on  the  any  of  measured  cognitive
performance  CSs  (t-values  ranged  between  -1.84  to  1.16).  BPRS  positive  symptoms
subscale  CSs was a  significant  predictor  for  SWM errors CSs (t = 2.17,  p < 0.05) and
information processing (RVP) CSs (t = -2.21, p < 0.05).   
Significant associations were found between mean daily AP DCs and patients’ performance
CSs  of  SOC,  and  SSP,  indicating  that  significant  improvement  occurred  as  AP  dose
decreased. Individual antipsychotic dose and psychopathology raw scores were significantly
correlated  at  both  baseline  and  follow-up  (r =  0.35,  p =  0.001;  r =  0.34,  p =  0.002,
respectively).
3.6. Correlation between objective and subjective cognitive functioning
No  significant  associations  were  found  between  objectively  and  subjectively  measured
cognitive functioning at baseline or follow-up (correlation coefficients ranged from r = -0.22
to  0.17,  p ≥  0.05).  Pearson’s  correlation  coefficient  between  baseline  and  follow-up
measurements of subjectively perceived cognitive functioning had low temporal stability (r
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= 0.20, p ≥ 0.05). Details about these correlation analyses are available on request from the
corresponding author.
4. Discussion
The  main  aim with  this  study was  to  analyse  whether  and  how cognitive  functionality
changes among 82 psychiatric patients directly after confirmation of an FEP diagnosis. In
these  data,  mean-level  changes  (deviations  from individuals’ predicted  scores  based  on
performances at the first testing occasion) occurred in episodic memory, processing speed,
mental  flexibility, and executive  functioning;  patients  tended to  maintain  their  cognitive
performance  relative  to  other  patients;  there  was  structural  stability  in  the  factors  that
summarised cognitive performance among FEP patients; and changes in cognitive test scores
were related to demographic and clinical characteristics. Furthermore, objectively measured
ability scores did not correlate with subjectively perceived cognitive functionality.
Detecting change in individual patient’s neuropsychological performances requires  the use
of appropriate methods. There are two specific types of change over time one can focus on:
rank-order change and mean-level change. A rank-order change refers to a change in an
individual’s cognitive  performance relative  to  other  individuals’,  and mean-level  change
refers to changes in average performance over time. The two are independent of each other,
i.e. perfect rank-order stability may characterise groups with substantial mean-level change,
because individuals often change in the same way. 
Limited information is available about the stability of the cognitive battery tests for different
groups of patients. Previous research addressing rank-order or mean-level stability between
two time points  of  the  CANTAB subtests  has  been scarce  and far  less  conclusive  than
research on the validity of the CANTAB among different samples, of which previous studies
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were mainly limited to  the general public and patients with diagnoses of schizophrenia or
dementia.
Mean-level change  
In terms of mean-level trends,  our results  appeared to  show that  spatial  recognition and
episodic memory declined over a six month period. In contrast, mental flexibility, executive
functioning, manipulation with items in one’s working memory, and information processing
speed seemed to improve. There was no evidence for changes in pattern recognition memory
or working memory capacity. The present study tends to corroborate previous suggestions
(Censits et al., 1997; Heaton et al., 2001; Rund, 1998) that there is no broad progression of
cognitive deficits during the initial stages of chronic psychotic disorders. This supports the
hypothesis of a primary neurodevelopmental deficit (Bora, 2015; Murray and Lewis, 1988;
Weinberger, 1987), which may be accompanied by the formation of disturbed regenerative
capacities  during  a  person’s  life-time  (Falkai  et  al.,  2015),  and  be  incorporated  with
epigenetic dysregulation, which is involved in neuronal plasticity mechanisms (Hasan et al.,
2013). 
Moreover, previous researchers have also demonstrated a cognitive improvement in CoS and
FEP patients  (Hoff et  al.,  2005;  Nopoulos  et  al.,  1994;  Rodríguez-Sánchez et  al.,  2008;
Olivier et al., 2015). However, one should consider the cognitive process being measured
and how this may change with repeated assessments (Heilbronner et al., 2010). Measures of
executive  functioning  generally  show  lower  mean-level  consistency.  Notably,  tests  of
executive  function  (IED,  SOC,  SWM)  rely  considerably  on  novelty.  Thus,  cognitive
improvements in FEP patients during the early course of the disease may be related to a
practice effect, a common process shared by CoS, and therefore an increase may not reflect
real cognitive improvement, but rather stability or deficit (Goldberg et al., 2007). 
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In terms of the paired association learning test (PAL), our results are in line with previous
studies that showed a decline in cognitive function during the early phases of FEP (Bilder et
al., 1992; Hoff et al., 1999), particularly in learning and memory, or the encoding stage of
memory formation (Cirillo and Seidman, 2003; Mesholam-Gately et al., 2009). With regard
to memory function,  Dikmen et al. (1999) argued that the lower consistency estimates for
memory test performances suggest memory itself may be substantially more variable than
other cognitive abilities. In contrast,  studies of FEP patients that have used memory and
learning subtests from the MATRICS (Measurement and Treatment Research to Improve
Cognition in Schizophrenia) Cognitive Consensus Battery  (Nuechterlein et al., 2004) have
detected improvements in the performance of visual learning and working memory tests
over a six month period (Olivier et al., 2015) or stable mean-levels over a year (Benoit et al.,
2014). Inconsistent findings between these studies could be owing to them having patient
groups  with  different  symptom  severities,  using  a  different  cognitive  functioning
measurement methodology, and employing different statistical methods.
Rank-order stability  
The magnitude of the rank-order coefficients in our study revealed high stability (r = 0.80 to
0.94) in the rank ordering of patients over time. Using a sample of 164 elderly volunteers, an
assessment of the CANTAB conducted at baseline and after four weeks by Lowe and Rabbit
(1998), revealed moderate stability indices for spatial memory score (r = 0.57) and executive
function (r = 0.60), good stability indices for PAL first trial memory score (r = 0.68), spatial
span length (r = 0.64), SWM total errors score (r = 0.68), and IED extradimensional shift
errors score (r = 0.70), and very high stability indices for pattern recognition memory score
(r = 0.84). Leeson et al. (2009b) evaluated temporal stability of the CANTAB executive tests
reliability over 1 and 3 years within 25 CoS and 104 patients with schizophrenia, and found
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lower test–retest  correlations  (r = 0.4–0.6).  Among a  smaller  sample  (58 subjects)  with
chronic  psychotic  disorder,  Barnett  et  al.  (2010)  reported  test–retest  correlations  on
executive  functioning  of  approximately  r =  0.6–0.8  after  intervals  of  12  to  14  weeks.
However, it is important to remember that test–retest correlations can vary depending on the
sample assessed, and the amount of time between test and retest (shorter retest intervals lead
to  higher  reliability  coefficients)  (Duff,  2012).  For  a  standard  neuropsychological
assessment,  there is  insufficient  empirical  data  to  produce appropriate  guidelines  on the
minimal  (or  maximal)  retest  interval  in  clinical  cases  (Heilbronner  et  al.,  2010).
Furthermore,  alternate  forms  of  tests  should  be  psychometrically  equivalent;  however,
evidence suggests this is not the case for many measures  (Lezak, 2012) and may result in
lower stability values. This problem did not emerge in our study, because the correlations
between scores on the parallel tests of PRM, SRM, PAL, and IED were very high (r = 0.80‒
0.94).
Among their other implications, the rank-order stability estimates can be seen as the lower-
bound reliability  estimates of  the CANTAB subtests:  their  actual  reliability  can only be
equal or higher, because the observed stability may have also reflected real change over
time.  The  magnitude  of  the  observed  estimates  supports  the  CANTAB  as  a  reliable
instrument to assess cognitive functioning in FEP patients.
Structure of cognitive function and measurement invariance 
In addition, a high level of rank-order stability implies that stable factors may be supporting
the maintenance of individual differences in cognitive functioning over time. Inspection of
the goodness-of-fit statistics for the one-factor model of FEP patients indicated the model
was a reliable representation of the data at the two time points. These results are consistent
with our previous study (Haring et al., 2015b), which examined the potential relationships of
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an identical set of variables between CoS and FEP patient samples, and demonstrated that a
broad latent ability factor model was the most appropriate representation of the relationships
between the neuropsychological variables among FEP patients compared to CoS, as well as
confirming  the  similar  findings  in  previous  studies  that  used  a  different  kind  of
neuropsychological  tests  (Censits  et  al.,  1997;  Dickinson et  al.,  2006) or  the  same test
battery  (Leeson  et  al.,  2009a).  The  results  of  the  invariance  analyses  indicate  that  the
structure  of  the  one-factor  solution  and  the  magnitude  of  the  correlation  between  the
observed  variables  (obtained  using  CANTAB)  and  the  latent  construct  was  invariant
between the baseline and follow-up assessments among the FEP patients, at  the level of
configural and weak invariance. The finding of invariance of the factor loadings, provides
empirical  evidence  to  support  the  assumption  that  test  scores  measured  an  invariant
psychological trait, and that latent factors had the same meaning after six months among
FEP patients. However, the observed scores’ intercepts were not invariant between the two
assessments, and misfit of scalar invariance suggest that comparisons of the factor means
should  be  interpreted  with  caution,  and  when  the  FEP  patients’  neuropsychological
performance is compared on a timeline, CANTAB subtest scores should be used. Of note is
that the same approach should be applied when FEP patients performance is compared with
CoS (Haring et al., 2015b). These mean differences may reflect the significant heterogeneity
of the patients’ psychopathology, treatment regimes, and or motivational level at one or more
time points. Moreover, one should take into consideration the possibility that among the FEP
patients group, there may be patients with different kinds of diagnoses according to further
disease course.
Correlations between cognitive stability and the other variables 
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Although heterogeneity in terms of mean-level change and high rank-order stability emerged
over a six month period, it is of theoretical, practical, and clinical importance to examine
how individuals differed from each other, and what variables, if any, could explain such
individual differences. 
Of the demographic characteristics taken into account, age and education seemed to have by
far the most important impact on cognitive performance. In our study, being younger had the
most prominent correlation with the paired associate learning subtest change scores (PAL),
which is consistent with previous results among healthy control subjects  (desRosiers and
Ivison, 1988). A longer time in education was a strong predictor of performance change at
the processing speed task (RVP). 
Gender differences in cognitive functioning are well known among healthy individuals. In
general, women tend to perform better than men at tasks measuring verbal abilities, whereas
the opposite is the case regarding visuospatial skills (Halari et al., 2005). However, a recent
review by Hyde (2016) suggests that males and females are quite similar in terms of most,
but not all cognitive variables, and gender differences can vary substantially in magnitude
with ages and the context in which the measurements occur. One of the most consistent
finding is that men are younger than women at the onset of a chronic psychotic disorder
(Eranti et al.,  2013). In the present study, although men’s mean age at onset was indeed
lower compared to women, the difference was not significant.    
Gender differences in cognitive functioning among patients with FEP are a controversial
issue (Albus et al., 1997; Hoff et al., 1998; Ittig et al., 2015). In this study, men made less
reverse errors at the set-shifting task, had better spatial executive functionality, higher spatial
span length, and used strategies more effectively than women. Regarding visual and spatial
recognition memory and paired associate learning, as well as information processing, men
and women performed equally. A similar trend in gender differences was traceable among
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the change scores of the tests. It is worth mentioning that we used computerised tests that
measure performance based on visuospatial abilities, and our findings on gender differences
are in accordance with previous reports of the generally better performance of male patients
in these domains  (Albus et  al.,  1997).  Among patients with schizophrenia,  Perlick et  al.
(1992) found that women had lower performance at attention tasks, and Roesch-Ely et al.
(2009)  demonstrated  that  women  scored  lower  than  men  on executive  functioning,  and
working  memory  tasks.  However,  some  previous  literature  has  reported  lower  overall
cognitive performance among males with schizophrenia (Goldstein et al., 1998; Seidman et
al., 1997) or a lack of gender difference among schizophrenia, and FEP patients (Hoff et al.,
1998; Ittig et al., 2015). There may be several factors that contribute to the heterogeneity of
the results of these studies. For example, when discussing gender differences, it is important
to consider the relative contributions of biological and psychosocial gender to the observed
effects. Men and women may vary in their symptoms of expression over the course of illness
and in response to treatment, and differences may be related to the selected study sample
(e.g. patients with chronic illness or FEP, and early- or late-onset schizophrenia patients)
(Mendrek  and  Mancini-Marïe,  2016).  In  addition,  we  suspected  that  aspects  of
psychopathology might differentially account for any differences in cognitive functioning
between  the  two  test  occasions.  The  associations  between  illness-dependent  symptom
dimensions and cognitive functioning have been widely studied, and findings suggest that
cognition is more closely associated with negative than positive symptoms (Heinrichs and
Zakzanis,  1998).  The  vast  majority  of  literature  suggests  that  negative  symptoms  and
executive functioning, verbal fluency, verbal memory, visual memory, attention, as well as
processing  speed  have  small  to  moderate  associations  (Dominguez  et  al.,  2009;
Nieuwenstein  et  al.,  2001;  Olivier  et  al.,  2015).  The  results  of  our  patients’  cognitive
functioning could not be attributed to changes in their negative symptoms. Consistent with
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our finding, Bell and Mishara (2006) demonstrated that changes in negative symptoms did
not predict  changes in  cognition,  and concluded that negative symptoms do not directly
cause cognitive impairment or vice versa. 
With regard to the relationships between positive symptoms and cognitive performance, the
literature  is  less  consistent.  The  meta-analytical  review  of  (Nieuwenstein  et  al.,
2001)Dominguez et al. (2009), suggested only a slight negative correlation occurs between
processing  speed  and  positive  symptoms  among  patients  with  schizophrenia,  whereas
Nieuwenstein  et  al.’s  (2001)  meta-analysis  found  no  associations  between  executive
functioning  and  positive  symptoms.  Recent  work  by  Olivier  et  al.  (2015)  found  that  a
decline  in  the  positive  symptom  dimension  score  of  FEP  patients  was  related  to
improvements in speed of processing, attention/vigilance, working memory, verbal memory,
verbal and visual learning, as well as reasoning and problem solving tasks. The same trend
was observed during other studies (Davidson et al., 2009; Trampush et al., 2015). Our results
revealed that improved performances at spatial working memory and processing speed tests,
were associated with lower positive symptom scores.  However,  we used both the broad
psychopathology rating scale (BPRS), as well as its negative and positive symptom scores,
to  evaluate  how  symptom  severity  and  any  changes  were  potentially  associated  with
cognitive performance over a six month period; these methodological aspects might also
explain  the  inconsistent  findings  with  previous  studies.  Specifically,  the  other  studies
employed  different  combinations  of  symptom  constructs  while  attempting  to  measure
ostensibly the same psychopathology.  
In addition, we found significant changes in negative and positive symptom scores at the six
month follow-up. Recent work by Ventura et al.  (2015) demonstrated that although there
was generally moderate stability in negative symptoms—assessed using BPRS and the Scale
for the Assessment of Negative Symptoms (SANS)  (Andreasen, 1984)—over a first year
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after recent-onset schizophrenia, a subgroup of patients (24%) had periods of  exacerbated
negative symptoms similar to positive symptom episodes. Furthermore, the prevalence of
enduring  negative  symptoms  in  FEP  patients  has  been  estimated  to  be  around  15%
(Kirkpatrick et al., 2001). Accordingly, this may suggest that negative symptoms have more
fluctuating nature among the subgroup of patients at  the early stage of the disease than
chronic  patients  and  consistency  between  association  studies  of  FEP patients  cognitive
functioning and negative symptom score might be lower. 
We found clinically meaningful and statistically significant correlations between AP dose
and BPRS ratings. The results indicate that patients with more severe treatment-refractory
symptoms, received higher doses during the both assessment. During the six month period
as patients continued to recover, psychopathology scores decreased, and as such AP doses
were gradually reduced. Although all patients at baseline were treated with atypical APs—
whereas  at  follow-up  four  patients  were  also  receiving  concomitantly  neuroleptics—we
analysed all patients homogenously in terms of medication. This was because it has been
previously established that  groups of  patients  treated  with a  combination of  typical  and
atypical APs showed very similar results to an only atypically medicated group (Ehlis et al.,
2007).  We found potential  impact  of  changes  to  CPZ equivalent  dosage on frontal  lobe
functionality:  reduced  doses  appeared  to  mediate  an  improvement  in  working  memory
capacity (SSP span length), as well as change towards enhanced executive functioning (SOC
problem  solving).  Previously,  Sota  and  Heinrich  (2003)  found  CPZ  equivalent  dose
negatively  related  to  learning  and  recall  abilities.  For  these  reasons,  clinicians  should
carefully consider changing drug doses in terms of quantity and or frequency it is taken,
when  psychopathology  severity  has  declined,  and  use  a  lowest-dose  strategy  whenever
possible.  However,  it  should  be  noted  that  a  subgroup  of  FEP patients  do  not  respond
sufficiently to antipsychotic treatment, and thus do not attain sufficient remission of positive
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and negative symptoms (Benoit et al., 2014; Ventura et al., 2011). Therefore, an individual
approach is recommended whenever any antipsychotic dosage change is considered.
Subjectively perceived compared to objectively measured cognitive performance
Evaluation of patients’ subjective experiences of cognitive functioning has so far received
too little scientific and everyday clinical attention. Existing studies have demonstrated that
self-assessed cognitive dysfunction is  prevalent  among patients with FEP  (Moritz  et  al.,
2000), which constitutes a clinically important dimension of the disorder (Homayoun et al.,
2011;  Stip  et  al.,  2003).  Moreover,  Chaytor  and  Schmitter-Edgecombe  (2003)  have
highlighted  problems  with  the  ecological  validity  of  traditional  neuropsychological
assessments, particularly in terms of their ability to reveal patients’ actual level of everyday
functioning, and have suggested not to assess the scope of cognitive functioning of psychotic
patients with only neuropsychological test performances. In addition, previous research on
subjective cognitive dysfunction mostly focused on patients with chronic illness; patients in
the  early  illness  stage  have  rarely  been investigated  in  this  regard  (Chang et  al.,  2015;
Ehmann et al., 2007; Moritz et al., 2000). Results of the present study are in line with others
(Chang et al., 2015; van den Bosch and Rombouts, 1998; Zanello and Huguelet, 2001), in
supporting  the  hypothesis  of  the  independence  of  self-perceived  cognitive  disturbances,
from objectively measured cognitive impairments,  among FEP patients.  The discrepancy
between  the  evaluations  of  subjective  and  objective  cognitive  functioning  suggests  that
patients’ subjective perceptions of their cognitive function have a different theoretical basis
than objective  indicators,  as  patients  do not  conceptualise  their  cognitive  functioning in
terms of distinct cognitive domains, as clinicians and neuropsychologists  do  (Stip et  al.,
2003).  Furthermore,  such  discrepancy  may  occur  owing  to  variations  in  methodology
(differences  in the subjective cognitive scales employed) and study design.  We used the
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SWN-K-E “Cognitive Functioning” subscale that comprises four simple statements about
self-perceived cognitive functioning. This subscale did not seem to appropriately correspond
to the specific cognitive test scores obtained using the CANTAB. In addition, one possible
explanation  for  the  low  inter-correlation  between  measurements  might  be  the  different
nature of the evaluations. The CANTAB tests were all visually presented to subjects and
high  performance  relied  on  visual  information  processing,  whereas  the  subjectively
perceived cognitive functioning items referred to much broader indicators including among
others verbal and arithmetical abilities, as well as semantic processing.       
However,  both  methods  (SWN-K  and  CANTAB  subtests)  have  been  validated  among
psychotic populations (Elliott et al., 1995; Haring et al., 2013; Haring et al., 2015b; Joyce et
al., 2005; Leeson et al., 2009a; Naber et al., 2001). In addition, awareness of one’s own
cognitive deficits could be affected by awareness of one’s condition as a mentally ill person,
and  schizophrenia  is  frequently  accompanied  by  a  lack  of  insight  (Pini  et  al.,  2001).
However,  the  literature  suggest  that  subjective  and objective  cognitive  tests  might  have
unique contributions, and thus both should be implemented to give a broader perspective
about a patient’s cognitive functioning to determine appropriate clinical practice regarding
assessment and management of cognitive problems.
The results of the present study should be interpreted whilst bearing in mind certain aspects
that  may  have  influenced  our  findings.  First,  the  recruited  patients  were  virtually
heterogeneous  in  terms  of  diagnosis,  medication,  and  duration  of  untreated  illness—
something which is difficult to avoid among any sample of FEP patients. Second, the sample
was restricted to a group of patients that were clinically stable and willing to participate in
the  study.  Our  findings  may  thus  not  generalise  to  the  overall  cognitive  performance
characteristics of patients with FEP in Estonia or beyond. Third, because we had a relatively
small sample size, we admit that our results about rank-order stability, mean-level change
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indices, and invariance analyses may not be representative of all FEP patients. In addition,
patients were at the early stages of the illness when cognitive performance was evaluated, so
results are not necessarily generalisable for different follow-up periods. Lastly, we did not
control  intra-individual  factors  that  may  influence  test–retest  consistency,  such  as  poor
motivation,  fatigue,  insufficient  sleep,  or  cigarette  smoking  prior  to  the  CANTAB  test
sessions. Despite these limitations, our research has some strengths, mainly related to the
natural  characteristics  of  the  FEP patients  sample,  and  the  longitudinal  design  used  to
evaluate changes in cognitive functioning over time, and the low level of drop-outs by the
follow-up period. 
In conclusion,  our  results  provide new information on the different  aspects  of cognitive
functioning during the early course of chronic psychotic disease. The findings suggest that
there  is  variability  in  the  type,  direction,  and size  of  the changes  of  different  cognitive
functions among FEP patients over time. We have also highlighted the need to examine the
factor  structure  of  the  neuropsychological  test  battery  and  the  level  of  measurement
invariance  when  cognitive  functioning  is  assessed  over  time,  and  our  results  contribute
valuable  data  regarding  usage  of  the  CANTAB among  FEP patients  groups.  Our  study
makes a case for clinicians and neuropsychologists to consider measurement invariance, as
well  as  patients’  demographic  and  clinical  characteristics,  when  assessing
neuropsychological change over time. Finally, the findings of the present study suggest that
subjective  and  objective  cognitive  deficits  are  two  distinct  constructs,  and  should  be
measured separately in order to attain a more comprehensive assessment of each patient’s
day-to-day functioning. In clinical practice they are probably complementary, even if not
directly comparable.
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Table 1. Longitudinal variability across multiple domains of cognitive functioning among 





stability (r)Estimate (SE) CI 
PRM 
Number correct
0.18 (0.14) (-0.08, 0.45) 1.35 0.89***
SRM
Number correct
-0.94 (0.15) (-1.24, -0.64) -6.20*** 0.94***
PAL
Memory score










0.42 (0.11) (0.20, 0.63) 3.80*** 0.82***
SSP
Span lenght
0.05 (0.11) (-0.17, 0.27) 0.49 0.92***
SWM 
  Total errors -0.42 (0.08) (-0.58, -0.27) -5.40*** 0.84***
SWM 
Strategy score 





0.29 (0.10) (0.10, 0.48) 2.96* 0.83***
aAll within-group comparisons were made controlling for the effects of education, age and 
gender. Random effects estimates between six month in cognitive functioning are expressed 
in effect size units (Cohen’s d), CI, confidence intervals of estimates (2.5%, 97.5%), SE, 
standard error, and rank-order stability (Pearson’ r). 
PRM, Pattern Recognition Memory; SRM, Spatial Recognition Memory; PAL, Paired 
Associates Learning; IED, Intra/Extradimensional Shift; SOC, Stockings of Cambridge; 
SSP, Spatial Span; SWM strategy, Spatial Working Memory, strategy score; SWM errors, 
Spatial Working Memory, errors score; RVP, Rapid Visual Information Processing. 
Negative parameter estimates (effect sizes) for SRM and PAL demonstrate decline in the 
performance and negative estimates for SWM and IED indices characterise lower scores but 
better performance during follow-up testing. Positive parameter estimates for PRM, SOC, 
SSP, and RVP reflect to the contrary higher scores and stability or better performance during 
follow-up. 
* p < .05, *** p < .001 
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Table 2. Summary of tests of factorial invariance in first episode psychosis patients group at 
baseline compared to follow-up testing according to one latent factor solution
Invariance χ2(df) Δχ² (Δdf) p-value CFI ΔCFI RMSEA
  Configural 
  Weak  

















χ2, chi-square; df, degree of freedom;  p-value corresponds to change in χ2 (Δχ²)¸ CFI, 
comparative fit index and change in CFI (ΔCFI); RMSEA, root mean square error of 
approximation. 
Table 3. Regression analysis for predictors (gender, age, education, psychopathology change






























































































































a Change score of the Brief Psychiatric Rating Score.
b Dose change of the used antipsychotic medications in chlorpromazine equivalents.
CI, confidence intervals of estimates (2.5%, 97.5%). 
PRM, Pattern Recognition Memory; SRM, Spatial Recognition Memory; PAL, Paired 
Associates Learning; IED, Intra/Extradimensional Shift; SOC, Stockings of Cambridge; 
SSP, Spatial Span; SWM strategy, Spatial Working Memory, strategy score; SWM errors, 
Spatial Working Memory, errors score; RVP, Rapid Visual Information Processing. 
* p < .05, ** p < .01
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Figure Captions
Fig. 1. Representation of the one-latent factor structural model derived from the exploratory 
factor analysis for first-episode psychosis patients . 
Variables in boxes represent observed measures and variable in oval represent latent 
variable. The paths from the latent constructs to the observed 
variables demonstrate the parameter estimates onto its representative constructs. 
The “e” represents the unique variance and error associated with each observed variable. 
PRM, Pattern Recognition Memory; SRM, Spatial Recognition Memory; PAL, Paired 
Associates Learning; SOC, Stockings of Cambridge; 
SSP, Spatial Span; SWM strategy, Spatial Working Memory, strategy score; SWM errors, 
Spatial Working Memory, errors score; 
IED, Intra/Extradimensional Shift; RVP, Rapid Visual Information Processing.
Fig. 2. Predicted mean levels of cognitive performance separately for men and women at 
baseline (a) and follow-up (b). Results are based on random coefficient models. 
PRM, Pattern Recognition Memory; SRM, Spatial Recognition Memory; PAL, Paired 
Associates Learning; IED, Intra/Extradimensional Shift; SOC, Stockings of Cambridge; 
SSP, Spatial Span; SWM strategy, Spatial Working Memory, strategy score; SWM errors, 
Spatial Working Memory, errors score; RVP, Rapid Visual Information Processing. Lower 
values (less errors and less ineffective strategy usage) for IED and SWM measures and 
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